VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY ON PLASMA CONCENTRATION IN NEWBORNS AND INFANTSGalli, Luisa MD*; Novelli, Andrea MD†; Chiappini, Elena PhD*; Gervaso, Paola MD*; Cassetta, Maria Iris BS†; Fallani, Stefania BS†; de Martino, Maurizio MD*The Pediatric Infectious Disease Journal: May 2007 - Volume 26 - Issue 5 - p 451-453 doi: 10.1097/01.inf.0000261111.90075.4d Brief Reports Abstract Author Information The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants. From the Departments of *Pediatrics and †Pharmacology, University of Florence, Florence, Italy. Accepted for publication February 7, 2007. Address for correspondence: Maurizio de Martino, MD, Department of Pediatrics, University of Florence, Florence, Italy. E-mail: firstname.lastname@example.org. © 2007 Lippincott Williams & Wilkins, Inc.